Investors in Vicarious Surgical have voted to shut down and liquidate the surgical robotics company immediately. CEO Stephen From, who joined in 2025, expressed frustration over the company's inability to reach a design freeze for its R&D program by the end of 2026, despite raising approximately $300 million since its inception.
The decision to liquidate comes after the company's market capitalization fell significantly, leading to its inclusion on the NYSE watch list for potential delisting. Vicarious Surgical's board cited ongoing operating losses and negative cash flows as reasons for the closure, with nearly $3.7 million in cash reported as of March 31, indicating insufficient funds to continue operations.
Looking ahead, Vicarious Surgical's assets will be auctioned off to settle outstanding obligations, and an assignee will oversee the liquidation process. The company reported total liabilities of $9 million and assets of $12.6 million, with significant losses in recent quarters, raising concerns about the future of its technology and potential buyers.
Editor's Note
The closure of Vicarious Surgical highlights the challenges faced by startups in the surgical robotics sector, particularly regarding funding and market viability. As the industry continues to evolve, the ability to secure financing and achieve critical development milestones remains crucial for success. This situation may prompt investors to reassess their strategies in the surgical robotics market.
Leave a comment